Despite the success of antiretroviral therapy (ART) in decreasing mortality for HIV-1-infected patients, ART has not cured the disease. A persistent viral reservoir in the T cells of HIV patients receiving potent ART is a significant barrier preventing eradication of HIV infection. We will briefly review what is known about the mechanisms that establish and maintain persistent HIV infection despite ART, to create a framework in which to consider approaches to the clearance or eradication of infection (“cure”), or to allow clinical stability in the absence of ART (“functional cure”). With regard to eradication therapies, it could be said that as a field our position is analogous to that of ART early in the HIV pandemic. As then we must now simultaneously develop and optimize platforms and paradigms for the discovery and testing of eradication therapies, and begin to advance candidate therapies toward human testing.
Get full access to this article
View all access options for this article.
References
1.
ChunT-W, FinziD, MargolickJ, ChadwickKet al.In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency. Nature Med, 1995; 12:1284–1290.
2.
ChunTW, StuyverL, MizellSBet al.Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA, 1997; 94:13193–13197.
3.
FinziD, HermankovaM, PiersonTet al.Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science, 1997; 278:1295–1300.
4.
WongJK, HezarehM, GunthardHFet al.Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science, 1997; 278:1291–1295.
5.
BlanksonJN, FinziD, PiersonTCet al.Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection. J Infect Dis, 2000; 182:1636–1642.
6.
ChunTW, EngelD, BerreyMMet al.Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci USA, 1998; 95:8869–8873.
DornadulaG, ZhangH, Van UitertBet al.Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA, 1999; 282:1627–1632.
9.
GunthardHF, HavlirDV, FiscusSet al.Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. J Infect Dis, 2001; 183:1318–1327.
10.
ZhangL, RamratnamB, Tenner-RaczKet al.Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med, 1999; 340:1605–1613.
11.
PalmerS, WiegandAP, MaldarelliFet al.New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol, 2003; 41:4531–4536.
12.
DinosoJB, KimSY, WiegandAMet al.Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci USA, 2009; 106:9403–9408.
13.
GandhiRT, ZhengL, BoschRJet al.on behalf of the AIDS Clinical Trials Group A5244 team. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: A randomized controlled trial. PLoS Med, 2010; 7,8:e1000321.
14.
WightmanF, SolomonA, KhouryGet al.Both CD31(+) and CD31 naive CD4(+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy. J Infect Dis, 2010; 202:1738–1748.
15.
CollmanR, HassanNF, WalkerRet al.Infection of monocyte-derived macrophages with human immunodeficiency virus type 1 (HIV-1). Monocyte-tropic and lymphocyte-tropic strains of HIV-1 show distinctive patterns of replication in a panel of cell types. J Exp Med, 1989; 170:1149–1163.
16.
OrensteinJM, FoxC, WahlSM. Macrophages as a source of HIV during opportunistic infections. Science, 1997; 276:1857–1861.
17.
ElleryPJ, TippettE, ChiuYLet al.The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol, 2007; 178:6581–6589.
18.
KeeleBF, TaziL, GartnerSet al.Characterization of the follicular dendritic cell reservoir of human immunodeficiency virus type 1. J Virol, 2008; 82:5548–5561.
19.
CarterC, Onafuwa-NugaA, McNamaraLet al.HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med, 2010; 16:446–445.
20.
ZhangJ, CrumpackerCS. Hematopoietic stem and progenitor cells in HIV/AIDS and immune reconstitution. Cell Res, 2010; 20:745–747.
21.
OteroM, NunnariG, LetoDet al.Peripheral blood dendritic cells are not a major reservoir for HIV type 1 in infected individuals on virally suppressive HAART. AIDS Res Hum Retroviruses, 2003; 19:1097–1103.
22.
PalmerS, MaldarelliF, WiegandAet al.Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA, 2008; 105:3879–3884.
23.
LambotteO, ChaixML, GasnaultJet al.Persistence of replication-competent HIV in the central nervous system despite long-term effective highly active antiretroviral therapy. AIDS, 2005; 19:217–218.
24.
YuklSA, ShergillAK, McQuaidKet al.Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS, 2010; 24:2451–2460.
25.
WilliamsSA, GreeneWC. Regulation of HIV-1 latency by T-cell activation. Cytokine, 2007; 39:63–74.
26.
HuangJ, WangF, ArgyrisEet al.Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med, 2007; 13:1241–1247.
27.
KlaseZ, KaleP, WinogradRet al.HIV-1 TAR element is processed by Dicer to yield a viral micro-RNA involved in chromatin remodeling of the viral LTR. BMC Mol Biol, 2007; 8:63.
28.
LassenKG, RamyarKX, BaileyJRet al.Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells. PLoS Pathog, 2006; 2:e68.
29.
HanY, LassenK, MonieDet al.Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol, 2004; 78:6122–6133.
30.
HanY, LinYB, AnWet al.Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. Cell Host Microbe, 2008; 4:134–146.
31.
LenasiT, ContrerasX, PeterlinBM. Transcriptional interference antagonizes proviral gene expression to promote HIV latency. Cell Host Microbe, 2008; 4:123–133.
32.
WeinbergerLS, BurnettJC, ToettcherJEet al.Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell, 2005; 122:169–182.
33.
JenuweinT, AllisCD. Translating the histone code. Science, 2001; 293:1074–1080.
34.
SmithKT, WorkmanJL. Introducing the acetylome. Nat Biotechnol, 2009; 27:917–919.
35.
SmithE, ShilatifardA. The chromatin signaling pathway: Diverse mechanisms of recruitment of histone-modifying enzymes and varied biological outcomes. Mol Cell, 2010; 4:689–701.
36.
Van LintC, EmilianiS, OttM, VerdinE. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J, 1996; 15:1112–1120.
37.
VerdinE, ParasJr, Van LintC. Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J, 1993; 12:3249–3259.
38.
CoullJ, RomerioF, SunJMet al.The human factors YY1 and LSF repress the human immunodeficiency virus type-1 long terminal repeat via recruitment of histone deacetylase 1. J Virol, 2000; 74:6790–6799.
39.
YlisastiguiL, CoullJJ, RuckerVet al.Polyamides reveal a role for repression in viral latency within HIV-infected donors' resting CD4+ T cells. J Infect Dis, 2004; 190:1429–1437.
40.
YlisastiguiL, ArchinNM, LehrmannGet al.Coaxing HIV-1 from resting CD4 T cells: Histone deacetylase inhibition allows latent viral expression. AIDS, 2004; 18:1101–1108.
41.
ImaiK, OkamotoT. Transcriptional repression of human immunodeficiency virus type 1 by AP-4. J Biol Chem, 2006; 281,18:12495–12505.
42.
JiangG, EspesethA, HazudaDJ, MargolisDM. c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol, 2007; 81:10914–10923.
43.
MarbanC, SuzanneS, DequiedtFet al.Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO J, 2007; 26:412–423.
44.
TyagiM, KarnJ. CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J, 2007; 26:4985–4995.
45.
WilliamsSA, ChenLF, KwonHet al.NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J, 2006; 25:139–149.
46.
ArchinNM, KeedyKS, EspesethAet al.Expression of latent human immunodeficiency virus type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS, 2009; 23:1799–1806.
47.
KeedyKS, ArchinNM, GatesATet al.A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol, 2009; 83:4749–4756.
48.
ArchinNM, EspesethA, ParkerDet al.Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses, 2009; 25:207–212.
49.
ContrerasX, SchwenekerM, ChenCSet al.Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem, 2009; 284:6782–6789.
50.
EdelsteinLC, Micheva-VitevaS, PhelanBD, DoughertyJP. Activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma. AIDS Res Hum Retroviruses, 2009; 25:883–887.
51.
MatalonS, PalmerBE, NoldMFet al.The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro. J Acquir Immune Defic Syndr, 2010; 54:1–9.
52.
YingH, ZhangY, LinSet al.Histone deacetylase inhibitor Scriptaid reactivates latent HIV-1 promoter by inducing histone modification in in vitro latency cell lines. Int J Mol Med, 2010; 26:265–272.
53.
du CheneI, BasyukE, LinYLet al.Suv39H1 and HP1gamma are responsible for chromatin-mediated V-1 transcriptional silencing and post-integration latency. EMBO J, 2007; 26:424–435.
54.
BlazkovaJ, TrejbalovaK, Gondois-ReyFet al.CpG methylation controls reactivation of HIV from latency. PLoS Pathog, 2009; 5:e1000554.
55.
KauderSE, BosqueA, LindqvistAet al.Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog, 2009; 5:e1000495.
56.
FriedmanJ, PearsonR, KarnJ. Direct evidence that histone trimethylation is required for HIV proviral silencing during the establishment of latency. Conf. Retrovir. Oppor. Infect., 2009Abstract 264.
57.
PearsonR, KimYK, HokelloJet al.Epigenetic silencing of human immunodeficiency virus (HIV) transcription by formation of restrictive chromatin structures at the viral long terminal repeat drives the progressive entry of HIV into latency. J Virol, 2008; 82:12291–12303.
58.
PagansS, KauderSE, KaehlckeKet al.The cellular lysine methyltransferase Set7/9-KMT7 binds HIV-1 TAR RNA, monomethylates the viral transactivator Tat, and enhances HIV transcription. Cell Host Microbe, 2010; 7:234–244.
59.
PagansS, PedalA, NorthBJet al.SIRT1 regulates HIV transcription via Tat deacetylation. PLoS Biol, 2005; 3:e41.
60.
BaileyJR, SedaghatAR, KiefferTet al.Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol, 2006; 80:6441–6457.
61.
BrennanTP, WoodsJO, SedaghatARet al.Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol, 2009; 83:8470–8481.
62.
SahuGK, PaarD, FrostSDet al.Low-level plasma HIVs in patients on prolonged suppressive highly active antiretroviral therapy are produced mostly by cells other than CD4 T-cells. J Med Virol, 2009; 81:9–15.
63.
ArchinNM, AndersonJ, KeedyKSet al.Persistent low-level viremia despite clinically successful antiretroviral therapy appears correlated with more frequent resting CD4+ T cell infection. XVIII International AIDS Conference, 2010Abstract WEPDA101.
64.
ChomontN, El-FarM, AncutaPet al.HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med, 2009; 15:893–900.
65.
BurnettJC, LimKI, CalafiAet al.Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol, 2010; 84:5958–5974.
66.
ReuseS, CalaoM, KabeyaKet al.Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: Implications for treatment of latent infection. PLoS One, 2009; 4:e6093.
67.
SavarinoA, MaiA, NorelliSet al."Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology, 2009; 6:52.
68.
MehlaR, Bivalkar-MehlaS, ZhangRet al.Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS One, 2010; 5:e11160.
69.
PerezM, de VinuesaAG, Sanchez-DuffhuesGet al.Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency. Curr HIV Res, 2010; 8:418–429.
70.
DentonPW, EstesJD, SunZet al.Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med, 2008; 5:e16.
71.
DentonPW, KriskoJF, PowellDAet al.Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PLoS One, 2010; 5:e8829.
72.
ChoudharySK, RezkNL, InceWLet al.Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2-/-{gamma}c-/- mouse. J Virol, 2009; 83:8254–8258.
73.
ShenA, ZinkMC, MankowskiJLet al.Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus–Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy. J Virol, 2003; 77:4938–4949.
74.
DinosoJB, RabiSA, BlanksonJNet al.A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J Virol, 2009; 83:9247–9257.
75.
ZinkMC, BriceAK, KellyKMet al.Simian immunodeficiency virus-infected macaques treated with highly active antiretroviral therapy have reduced central nervous system viral replication and inflammation but persistence of viral DNA. J Infect Dis, 2010; 202:161–170.
76.
ClementsJE, BabasT, MankowskiJLet al.The central nervous system as a reservoir for simian immunodeficiency virus (SIV): Steady-state levels of SIV DNA in brain from acute through asymptomatic infection. J Infect Dis, 2002; 186:905–9013.
77.
NorthTW, HigginsJ, DeereJDet al.Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol, 2010; 84:2913–2922.
